AbbVie Inc (ABBV)vsenVVeno Medical Corp (NVNO)
ABBV
AbbVie Inc
$258.09
-1.81%
HEALTHCARE · Cap: $442.36B
NVNO
enVVeno Medical Corp
$11.24
-1.99%
HEALTHCARE · Cap: $7.03M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
NVNO
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$258.08
$106.59 premium
Intrinsic value data unavailable for NVNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : NVNO
The strongest argument for NVNO centers on Price/Book, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : NVNO
The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVNO carries more volatility with a beta of 1.05 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 27/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
enVVeno Medical Corp
HEALTHCARE · MEDICAL DEVICES · USA
enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?